10-Q: Schrodinger Q3 2025: Revenue Surges, Losses Shrink Amid Pipeline Shifts

Schrodinger, Inc. reported a 54% revenue increase to $54.3 million in Q3 2025 and a narrowed net loss, driven by strong drug discovery and software growth, despite discontinuing a key clinical program.

Summary

• Total revenues increased 54% to $54.3 million for the three months ended September 30, 2025, and 41% to $168.6 million for the nine months ended September 30, 2025, compared to the same periods in 2024.
• Net loss improved to $32.8 million for the three months ended September 30, 2025, from $38.1 million in the prior year, and to $135.8 million for the nine months from $146.9 million in the prior year.
• Operating cash flow significantly improved, providing $30.0 million for the nine months ended September 30, 2025, compared to using $126.3 million in the prior year period.
• The company discontinued the clinical development program for SGR-2921 (CDC7 inhibitor) in August 2025 due to safety concerns, including two patient deaths.
• A restructuring initiative in May 2025 reduced the workforce by approximately 60 employees (7% of full-time staff), expected to save $30 million annually in operating expenses.
• SGR-1505 (MALT1 inhibitor) showed preliminary clinical activity in Phase 1, received Fast Track and Orphan Drug designations for Waldenström macroglobulinemia, and Orphan Drug designation for mantle cell lymphoma.
• Dosing began in a Phase 1 clinical trial for SGR-3515 (Wee1/Myt1 inhibitor) in advanced solid tumors in July 2024, with initial data expected in the first half of 2026.
• The Novartis collaboration, initiated in November 2024, included a $150.0 million upfront payment received in January 2025 and potential milestones up to $2.272 billion.

Sentiment

Score: 7

Explanation: The company demonstrated strong revenue growth and a significant improvement in operating cash flow, alongside progress in its key drug discovery programs (SGR-1505 and SGR-3515). While a clinical program (SGR-2921) was discontinued due to safety, and net losses persist, the overall financial trajectory and strategic adjustments (restructuring) indicate positive momentum and a solid liquidity position.

Positives

• Total revenues increased by 54% to $54.3 million for the three months ended September 30, 2025, compared to $35.3 million in the prior year.
• Drug discovery revenue surged by 295% to $13.5 million for Q3 2025, primarily due to the Novartis collaboration.
• Software products and services revenue grew by 28% to $40.9 million for Q3 2025, driven by increased spend from existing hosted customers and new subscriptions.
• Net loss significantly narrowed to $32.8 million in Q3 2025 from $38.1 million in Q3 2024.
• Operating cash flow turned positive, providing $29.992 million for the nine months ended September 30, 2025, a substantial improvement from using $126.255 million in the same period last year.
• SGR-1505 (MALT1 inhibitor) demonstrated preliminary clinical activity with a 22% overall response rate in patients with relapsed or refractory B-cell malignancies.
• SGR-1505 received Fast Track designation for Waldenström macroglobulinemia in June 2025 and Orphan Drug designation for Waldenström macroglobulinemia in October 2025, in addition to its August 2023 Orphan Drug designation for mantle cell lymphoma.
• The company maintains a strong liquidity position with $401.0 million in cash, cash equivalents, restricted cash, and marketable securities as of September 30, 2025.
• The restructuring initiative is expected to reduce operating expenses by approximately $30 million on an annualized basis.

Negatives

• The company continues to incur significant operating losses, with a net loss of $32.8 million in Q3 2025 and $135.8 million for the nine months ended September 30, 2025.
• Accumulated deficit increased to $661.3 million as of September 30, 2025, from $525.5 million at December 31, 2024.
• The clinical development program for SGR-2921 (CDC7 inhibitor) was discontinued in August 2025 due to safety concerns, including two emergent events where SGR-2921 was considered to have contributed to two deaths in patients with AML.
• Gain on equity investments decreased significantly, with a $9.7 million gain in Q3 2025 compared to $25.5 million in Q3 2024, and a $1.2 million gain for the nine months in 2025 compared to $27.8 million in 2024.
• Total deferred revenue decreased to $174.7 million as of September 30, 2025, from $220.8 million at December 31, 2024.
• Investing activities used $13.5 million in cash for the nine months ended September 30, 2025, a shift from providing $125.4 million in the prior year (which included Morphic disposition proceeds).

Risks

• History of significant operating losses and expectation to incur losses over the next several years.
• Inability to increase software sales, increase revenue from drug discovery collaborations, or successfully develop and commercialize drug products.
• Quarterly and annual results may fluctuate significantly, impacting common stock value.
• Risk of existing customers not renewing licenses, not buying additional solutions, or renewing at lower prices.
• Significant portion of revenues generated by sales to life sciences industry customers, making the business vulnerable to adverse factors affecting this industry.
• Highly competitive markets for molecular discovery and design software.
• Uncertainty of return on investment of resources and cash in drug discovery collaborations.
• Computational platform may not result in the discovery and development of commercially viable products.
• Failure to identify, discover, or develop product candidates or capitalize on greater commercial opportunities.
• Very limited experience in clinical development as a company.
• Likely requirement for additional capital to fund operations, with no guarantee of acceptable terms or success.
• Difficulty enrolling a sufficient number of patients in clinical trials.
• Reliance on third parties (CROs) to conduct clinical trials, with risks of unsatisfactory performance or missed deadlines.
• Outcome of preclinical studies and early clinical trials may not be predictive of later clinical trial success.
• Failure to comply with obligations under existing or future intellectual property licenses could lead to loss of important IP rights.
• Inability to obtain, maintain, enforce, and protect patent protection for technology and product candidates.
• Internal information technology systems or those of third-party vendors may fail or suffer security breaches.
• Future success depends on ability to retain key executives and attract, retain, and motivate qualified personnel.
• Difficulties in managing multiple business units and growth due to pursuing multiple strategies simultaneously.
• Executive officers, directors, and principal stockholders have the ability to influence all matters submitted to stockholders for approval.
• Actual operating results may differ significantly from guidance.
• Doing business internationally creates operational and financial risks.
• Operations may be interrupted by natural disasters or catastrophic events.
• Changes in tax laws or their implementation/interpretation could adversely affect business and financial condition.
• Ability to use Net Operating Losses (NOLs) and research and development tax credit carryforwards may be limited.
• International operations subject to potentially adverse tax consequences.
• Risk of taxing authorities asserting sales and use, value-added, or similar taxes.
• Unanticipated changes in effective tax rate could harm future results.
• Acquisitions could divert management's attention, result in dilution, and disrupt operations.
• Defects or disruptions in solutions could diminish demand and lead to liability.
• Reliance on third-party cloud-based infrastructure.
• Security measures may be breached or unauthorized access obtained.
• Failure to offer high-quality technical support services.
• Solutions utilize third-party open-source software, with compliance risks.
• Obligations under collaboration agreements may limit intellectual property rights.
• Intellectual property rights do not guarantee commercial success.
• Involvement in lawsuits to protect or enforce patent or other intellectual property rights.
• Third parties may initiate legal proceedings alleging infringement of their intellectual property rights.
• Inability to protect the confidentiality of trade secrets.
• Additional competitors could enter the market with generic versions of products if regulatory approval is obtained.
• Regulatory approval process is expensive, time-consuming, and uncertain.
• Failure to obtain marketing approval in foreign jurisdictions.
• Accelerated development pathways may not lead to expedited approval.
• Orphan drug exclusivity may not prevent the FDA or EMA from approving other competing products.
• Terms of approvals and ongoing regulation could require substantial expenditure of resources and limit manufacturing/marketing.
• Government investigations of alleged violations of law.
• Disruptions at the FDA and other government agencies from funding cuts, personnel losses, regulatory reform, and government shutdowns.
• Current and future legislation may increase the difficulty and cost to obtain reimbursement for product candidates.
• Prices of prescription pharmaceuticals are subject to considerable legislative and executive actions.
• Compliance with global privacy and data security requirements could result in additional costs and liabilities.
• Subject to anti-corruption laws, export control laws, customs laws, sanctions laws, and other laws governing operations.
• Changes in and uncertainty surrounding U.S. and international trade policies, particularly with respect to China.
• Employees, independent contractors, consultants, and vendors may engage in misconduct or other improper activities.
• Climate change-related risks and uncertainties.
• Price of common stock is volatile and fluctuates substantially.
• Sales of a substantial number of shares of common stock could cause the market price to drop significantly.
• Increased costs as a result of operating as a public company.
• Failure to maintain proper and effective internal control over financial reporting.
• Disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
• Provisions in corporate charter documents and Delaware law could make an acquisition more difficult.
• Certificate of incorporation designates Delaware courts as sole and exclusive forum for certain actions.

Future Outlook

The company expects operating expenses to increase substantially in the foreseeable future due to continued investments in proprietary drug discovery programs, sales and marketing infrastructure, and the computational platform. Future capital requirements will depend on software revenue growth, R&D spending, milestone payments from collaborations, and the advancement of proprietary drug discovery programs. The company believes its existing cash, cash equivalents, and marketable securities are sufficient to fund operating expenses and capital expenditure requirements through at least the next 24 months, but may seek additional financing due to market conditions or strategic considerations. Initial data from the SGR-3515 Phase 1 clinical trial is anticipated in the first half of 2026, and additional clinical data for SGR-1505 will be presented in December 2025. The company does not intend to initiate additional clinical trials or advance other internal preclinical programs independently beyond SGR-1505 and SGR-3515.

Management Comments

• "We are transforming the way therapeutics and materials are discovered."
• "Over the last decade, we have entered into a number of collaborations with leading biopharmaceutical companies that have provided us with significant revenue and have the potential to produce additional milestone payments, option fees, and future royalties."
• "In 2018, we began to develop a pipeline of proprietary drug discovery programs with the goal of using our platform to produce a portfolio of novel, high value therapeutics."
• "Based on the initial data, SGR-1505 was observed to be well-tolerated with no dose-limiting toxicities or deaths due to treatment-emergent adverse events."
• "SGR-1505 demonstrated preliminary clinical activity, and responses were observed in multiple histologies."
• "We are exploring strategic opportunities to advance the clinical development of SGR-1505."
• "Despite early evidence of monotherapy activity observed in the Phase 1 clinical trial [for SGR-2921], based on the profile observed prior to discontinuation, including two emergent events where SGR-2921 was considered to have contributed to two deaths in patients with AML, we believed the path to development as a combination therapy would be difficult to pursue."
• "The phasing out of independent clinical development activities and associated cost reductions, together with the restructuring of our operations... are expected to result in savings of approximately $70 million and further improve and enhance our operational efficiency."
• "We believe our existing cash, cash equivalents, and marketable securities as of September 30, 2025 will be sufficient to fund our operating expenses and capital expenditure requirements through at least the next 24 months."

Industry Context

The biopharmaceutical industry is highly regulated, competitive, and experiencing consolidation, with increasing competition from companies utilizing artificial intelligence (AI) and other computational approaches for drug discovery. Regulatory changes, such as the EU Clinical Trials Regulation (CTR) and potential revisions to EU pharmaceutical legislation (new Pharma Package), are impacting clinical trial conduct and market exclusivity. U.S. legislative and executive actions, including the Inflation Reduction Act (IRA) and the One Big Beautiful Bill Act (OBBBA), are influencing drug pricing, R&D expensing, and potentially shifting investment towards biologics over small molecules. Recent U.S. Supreme Court decisions (Loper Bright, Corner Post, Jarkesy) introduce uncertainty into the regulatory process and may lead to increased legal challenges against federal agencies like the FDA. Geopolitical tensions and trade policies (e.g., U.S. tariffs on China, BIOSECURE Act) could disrupt supply chains and increase costs for pharmaceutical ingredients and manufacturing.

Comparison to Industry Standards

• The company faces competition in molecular discovery and design software from companies including BIOVIA (Dassault Systèmes SE), Chemical Computing Group (US) Inc., Cresset Biomolecular Discovery Limited, Cadence Design Systems, Inc., Optibrium Limited, Cyrus Biotechnology, Inc., Molsoft LLC, Insilico Medicine, Inc., Iktos, XtalPi Inc., AbCellera, Inductive Bio, Inc., Chemaxon, PerkinElmer, Inc., and Simulations Plus, Inc.
• In materials science, competitors include BIOVIA and Materials Design, Inc.
• In enterprise software for life sciences, competitors include BIOVIA, Certara USA, Inc., Chemaxon, Revvity, Inc., and Dotmatics, Inc.
• For its MALT1 inhibitor (SGR-1505), competitors include AbbVie Inc., HotSpot Therapeutics, and Recursion Pharmaceuticals, Inc., as well as other treatments for B-cell malignancies like bi-specifics and CAR-Ts.
• For its Wee1/Myt1 inhibitor (SGR-3515), competitors include Zentalis Pharmaceuticals, Debiopharm International SA, IMPACT Therapeutics, Inc., Shouyao Holdings Co. Ltd., BioCity Biopharma, Aprea Therapeutics, Inc., Repare Therapeutics Inc. (Myt1 inhibitor), and Acrivon Therapeutics, Inc. (Wee1/Myt1 inhibitor).
• No specific global benchmarks or direct comparative results are provided in the filing to assess performance against industry standards.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently subject to any material legal proceedings.

Related Party Transactions

• Paid consulting fees of $109,000 for the three months and $328,000 for the nine months ended September 30, 2025, to a member of its board of directors.
• Recognized $292,000 (three months) and $1,003,000 (nine months) in drug discovery contribution revenue related to an agreement with the Bill & Melinda Gates Foundation for women's health.
• Recognized $2,731,000 (three months) and $11,088,000 (nine months) in software contribution revenue related to agreements with the Bill & Melinda Gates Foundation to fund the expansion of the computational platform for toxicity prediction.
• Recognized $2,200,000 (three months) and $2,200,000 (nine months) in software contribution revenue from Gates Ventures, LLC, an entity under the control of William H. Gates III, a beneficial owner of more than 5% of the company's voting securities.

Stakeholder Impact

• Shareholders: Potential for stock price volatility due to mixed results and inherent drug discovery risks, but also potential for capital appreciation from strong revenue growth and pipeline advancements. Dilution risk from potential future equity raises.
• Employees: Workforce reduction of approximately 60 employees (7% of full-time staff) due to restructuring, impacting those affected. Remaining employees may benefit from improved operational efficiency and focused strategic direction.
• Customers: Continued development and enhancement of software solutions, but potential for service disruptions or security breaches could impact customer confidence. Drug discovery collaborations continue to advance, offering potential new therapeutics.
• Suppliers/Creditors: Improved operating cash flow and strong liquidity position enhance the company's financial stability, potentially benefiting creditors. Geopolitical risks and trade policies could impact supply chains.
• Patients: Discontinuation of SGR-2921 means a potential therapeutic option is no longer being pursued. Progress with SGR-1505 and SGR-3515 offers hope for future treatments in oncology and B-cell malignancies.

Next Steps

• Present additional clinical data from the SGR-1505 Phase 1 clinical trial at the American Society of Hematology Annual Meeting in December 2025.
• Anticipate reporting initial data from the SGR-3515 Phase 1 clinical trial in the first half of 2026.
• Explore strategic opportunities to advance the clinical development of SGR-1505.
• Continue to invest in activities related to discovery and development of proprietary drug discovery programs, advancing the computational platform, and hiring additional personnel.
• Comply with new accounting standards: ASU 2023-09 (Income Taxes) effective for annual periods beginning after December 15, 2024; ASU 2024-03 (Income Statement Expenses) effective for annual periods beginning after December 15, 2026; ASU 2025-05 (Credit Losses) effective for annual reporting periods beginning after December 15, 2025; ASU 2025-07 (Derivatives and Hedging, Revenue) effective for annual reporting periods beginning after December 15, 2026.

Key Dates

Recommendation

The company demonstrated strong revenue growth in both its software and drug discovery segments, significantly narrowed its net loss, and achieved positive operating cash flow for the nine-month period. Key drug candidates like SGR-1505 received important regulatory designations and showed preliminary clinical activity. However, the discontinuation of the SGR-2921 program due to safety concerns highlights the inherent risks in drug development. While the restructuring efforts are expected to improve operational efficiency and the company maintains a solid cash position, the accumulated deficit continues to grow, and future profitability remains uncertain given the substantial R&D investments required. The stock is a 'Hold' as the positive momentum is balanced by the high-risk nature of drug discovery and the need for sustained execution to achieve long-term profitability.

Keywords

computational platform, drug discovery, software, biopharmaceutical, AI, machine learning, MALT1 inhibitor, Wee1/Myt1 inhibitor, oncology, neurology, immunology, SEC filing, 10-Q, clinical trials, pharmaceuticals